Modern Action logo
IssuesBillsBriefing
Donate
Donate
Modern Action

Navigation

Menu

01HomeFront page→02IssuesActive issue pages→03BillsLegislation index→04BriefingDaily context→05DonateSupport the work→

Account

Sign In→Get Started→
Modern Action

Find the bills behind the news, understand what Congress can do, and contact your representatives with a specific message.

Platform

  • Contact Congress
  • Write to Congress
  • Browse Bills
  • Track Bills

Resources

  • Find My Representatives
  • Contact My Representatives
  • How to Contact Representatives
  • Does Contacting Congress Work?

Support

  • Contact Us
  • Accessibility

Legal

  • Privacy Policy
  • Terms of Service
  • Cookie Policy
  • Accessibility

Stay informed about legislation

Get weekly updates on important bills and how to take action.

© 2026 Modern Action. All rights reserved.

Made with ❤️ for democracy
All systems operational

Contact Congress about H.R. 8890: Enhancing CLIA Act of 2026

Many lab-made medical tests would be regulated mainly through CLIA, the federal lab quality system. Labs would need evidence that tests work, report serious errors, and submit test details to a federal database.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Enhancing CLIA Act of 2026 is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest action on H.R. 8890: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Who this affects: This bill mainly affects clinical labs that create or run their own medical tests. It also affects doctors and patients who rely on those results for diagnosis or treatment. Medicare, drug makers, biologic makers, FDA, and the Department of Health and Human Services would also work under new rules tied to CLIA-based test review.

Why this matters: This bill matters because lab-made tests can shape major care decisions, and the bill changes who checks them and how. It may make the path for new tests more predictable for labs. It may also reduce FDA’s direct role in reviewing some higher-risk tests. The final impact on patient safety, test access, cost, and innovation would depend on future rules and enforcement.

Key provisions in H.R. 8890

  • The bill would move the main federal oversight of laboratory developed tests, or LDTs, to CLIA. CLIA is the federal law that sets quality rules for clinical labs, instead of treating these tests as medical devices under FDA device law.
  • The bill would define what counts as a laboratory developed test. It would also say these tests are not “devices” under federal device law, with limited transition rules for tests FDA has already reviewed.
  • Starting two years after the bill becomes law, labs could run an LDT only if it meets the right proof standard. All such tests must show analytical validity, meaning they measure what they claim to measure. Tests used for patient care must also show clinical validity, meaning the result has real medical meaning.
  • Labs could choose to ask an approved outside reviewer for a supplemental affirmation. That is an optional finding that the test meets the standard. FDA could serve as one of these reviewers, but only within the CLIA-based system.
  • The Secretary of Health and Human Services would approve outside reviewers. The process must be risk-based and rigorous. Reviewers would have to notify the Secretary if a test appears unsafe, lacks evidence, or is marketed with deceptive claims.

How Modern Action helps you take action on H.R. 8890

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 8890

What is H.R. 8890?
Many lab-made medical tests would be regulated mainly through CLIA, the federal lab quality system. Labs would need evidence that tests work, report serious errors, and submit test details to a federal database.
How do I support or oppose H.R. 8890?
Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.
Who should I contact about H.R. 8890?
Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.
Can Modern Action explain H.R. 8890 before I act?
Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.